Novo Nordisk sues Eli Lilly, alleging deceptive ads that misrepresent GLP-1 drug efficacy
Novo Nordisk filed a lawsuit in federal court in New Jersey accusing Eli Lilly of running a deceptive advertising campaign.
The complaint says Lilly’s ads compare the highest doses of its weight‑loss drug Zepbound and diabetes drug Mounjaro with lower doses of Novo’s Wegovy and Ozempic, creating a misleading impression of relative effectiveness.
Novo argues the ads rely on outdated clinical trial data, which it claims inflates the perceived benefits of Lilly’s products.
The filing marks an escalation in the ongoing rivalry between the two companies in the fast‑growing GLP‑1 market.
The case could have broader implications for how obesity and diabetes drugs are marketed, though no court ruling has been issued yet.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’”
read at STAT ↗
comments(0)
5-min edit window · permanent after that